Descrizione Clinica
Bench drugs Ljlacto 6cps vag 100000000ufc
MILK 100.000.000 UFC VAGINALLY SOFT CAPSULES
active ingredients
• Each vaginal capsule contains: Active ingredient: Lactobacillus plantarum P 17630 at least 108 UFC. For the full list of excipients, see paragraph 6.1Excellent
• Each vaginal capsule contains: Sodium p-oxybenzoate ethyl - Sodium p-oxybenzoate ethyl - Medium chain triglycerides - Silice (Aerosil 300) - Gelatin - Glicerol - Dimethylpolisylossano - Titanium bioxide (E 171) - Lactose - Crioprotector (Silver milk - Saccarosium - Sorbitol - Ascorbate sodium).Therapeutic indications
LJLACTO vaginal soft capsules finds indication in the “vaginiti and vulvo-vaginiti” in general, as the lactobacilli in them present, implanting and multiplying on the vaginal mucosa, as well as bringing back to balance the bacterial flora autochthonous, indirectly by competition, colonization by pathogenic germs. LJLACTO is therefore used, starting from the fertile age, in the topical therapy of vaginal infections supported by pathogenic germs. In particular in vaginitis associated with ovarian insufficiency, hypofollicolinic leucorrea, senile vaginiti, vulvarious itching, vaginal dystrophy. LJLACTO is also used as an adjuvant in chemotherapy and antibiotic treatment in vaginitis from Trichomonas.Contraindications
Hypersensitivity to the active ingredient or any excipientPopulation
• A vaginal capsule a day. Mode of use: Introduce a capsule deeply into the vagina, in supine position, the evening before bedtime.Conservation
Store the medicine at a temperature between + 2°C and + 8°C.Warnings
The use, especially if prolonged, of products for topical use can give rise to phenomena of sensitization and produce unwanted effects. In this case you must stop the treatment and consult your doctor. LJLACTO does not replace antibiotic therapy or chemotherapy, but it represents a useful complement by restoring, especially at the end of the specific treatment, the physiological conditions of the vaginal environment. Keep the medicine out of reach and view of childrenInteractions
No interaction studies have been carried out.Effects
Undesirable effects related to the use of the medicinal product have not been reported. Reporting of suspicious adverse reactions. The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.agenziafarmaco.gov.it/it/responsabili.Overdosing
No overdose cases have been reported.The Lactobacillus plantarum is a regular non-pathogenic host of the vagina, so LJLACTO can be used in pregnancy and/or during breastfeeding.
Source: Farmadati
